癌症研究中抑制血管新生療法及血管標的療法相關未來競爭力趨勢

癌症研究中抑制血管新生療法及血管標的療法相關未來競爭力趨勢 是由出版商BioSeeker Group AB在2006年10月所出版的。 這份英文市場調查報告書包含125 pages 價格從美金2828起跳。

簡介

目錄

Abstract

Introduction

With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.

Scope of this report

• In-depth competitive landscape assessment of the anti-angiogenesis market in oncology
• Thorough review of utilized targets in anti-angiogenic and vascular target drug development
• Thorough review of approved drugs
• Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

• Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in onoclogy, but they just constitute 10% of the competitors in the field.
• More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.
• The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations, BioSeeker identifies that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.

Key reasons to read this report

• Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs
• Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.
• Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Some of the almost 100 drugs included in this analysis

2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc.

Some of the more than 100 companies included in this analysis

Adherex, Aeterna Zentaris, Amgen, AstraZeneca, Bayer, Celgene, Chugai, Eli Lilly, EntreMed, Eisai, Exelixis, Genaera, Genentech, Hoffmann-La Roche, Merck KGaA, Novartis, OXiGENE, PDL BioPharma, PharmaMar, Wilex etc.

Table of Contents

1. Executive Summary

2. Cancer Highlights

3. Methodology

4. Table of Contents

• 4.1 List of Boxes
• 4.2 List of Figures
• 4.3 List of Tables

5. Introduction

• 5.1 Neoplastic Angiogenesis & Tumor Vasculature
  • 5.1.1 Tumor Vasculature
  • 5.1.2 The Current Model of Sprouting Angiogenesis
• 5.2 Main Angiogenic Factors
  • 5.2.1 Vascular Endothelial Growth Factor
  • 5.2.2 The Angiopoietins and Platelet Derived Growth Factor
  • 5.2.3 Integrins in Angiogenesis
  • 5.2.4 Inhibitors of Angiogenesis
• 5.3 Vascular Targeting Agents
• 5.4 Vascular Disruptive Agents

6. Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology

• 6.1 Countries & Players: Who are In the Lead?
  • 6.1.1 Top 10 Players Dominate The Developmental Pipeline
• 6.2 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
  • 6.2.1 Review of Deals and Alliances Initiated in 2005
  • 6.2.2 Review of Deals and Alliances Initiated in 2004
  • 6.2.3 Review of Deals and Alliances Initiated in 2003

7. Approved Anti-Angiogenic Cancer Drugs: Performance

8. Target Analysis in Anti-Angiogenesis and Vascular Targeting

• 8.1 Targets of Late Stage Anti-Angiogenic Drugs in Development
  • 8.1.1 Drugs with Epidermal Growth Factor Receptor as a Target
  • 8.1.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
  • 8.1.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
  • 8.1.4 Drugs with Kinase Insert Domain Receptor as a Target
  • 8.1.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
  • 8.1.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
  • 8.1.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
  • 8.1.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
  • 8.1.9 Drugs with Protein Kinase C, beta 1 as a Target
  • 8.1.10 Drugs with Ret Proto-Oncogene as a Target
  • 8.1.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as Target
  • 8.1.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
  • 8.1.13 Drugs with Vascular Endothelial Growth Factor as a Target
• 8.2 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
  • 8.2.1 Targets in Breast Cancer
  • 8.2.2 Targets in Colorectal Cancer
  • 8.2.3 Targets in Lung Cancer
  • 8.2.4 Targets in Prostate Cancer
  • 8.2.5 Targets in Renal Cancer

9. Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications

• 9.1 General Drug Developmental Overview
• 9.2 Progress Analysis - Breast Cancer
  • 9.2.1 Phase I Clinical Development
  • 9.2.2 Phase II Clinical Development
  • 9.2.3 Phase III Clinical Development
• 9.3 Progress Analysis - Colorectal Cancer
  • 9.3.1 Phase I Clinical Development
  • 9.3.2 Phase II Clinical Development
  • 9.3.3 Phase III Clinical Development
• 9.4 Progress Analysis - Lung Cancer
  • 9.4.1 Phase I Clinical Development
  • 9.4.2 Phase II Clinical Development
  • 9.4.3 Phase III Clinical Development
• 9.5 Progress Analysis - Prostate Cancer
  • 9.5.1 Phase I Clinical Development
  • 9.5.2 Phase II Clinical Development
  • 9.5.3 Phase III Clinical Development
• 9.6 Progress Analysis - Renal Cancer
  • 9.6.1 Phase I Clinical Development
  • 9.6.2 Phase II Clinical Development
  • 9.6.3 Phase III Clinical Development

10. Disclaimer

• 10.1 Liability
• 10.2 Completeness .

11. Appendix I: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology

12. Drug Index

13. Company Index

4.1 List of Boxes

• Box 1: Nexavar's Clinical Data That Lead To Its EMEA Approval Myeloma
• Box 2: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
• Box 3: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
• Box 4: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
• Box 5: Business & Market - Cilengitide
• Box 6: Business & Market - Exherin
• Box 7: Business & Market - WX-UK1
• Box 8: Business & Market - Combretastatin A-4 phosphate
• Box 9: Business & Market - GCS-100LE
• Box 10: Business & Market - PTK/ZK
• Box 11: Business & Market - AS-1404
• Box 12: Business & Market - Phosphomannopentaose sulfate
• Box 13: Business & Market - Squalamine
• Box 14: Business & Market - talactoferrin alfa
• Box 15: Business & Market - ZD-6474
• Box 16: Business & Market - AP-23573
• Box 17: Business & Market - Volociximab
• Box 18: Business & Market - XL-999

4.2 List of Figures

• Figure 1: Establishment of Blood Supply to Tumors
• Figure 2: Sprouting Angiogenesis
• Figure 3: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
• Figure 4: Top 10 Companies' Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
• Figure 5: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
• Figure 6: Annual Sales of Avastin on US and Non US Markets
• Figure 7: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
• Figure 8: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
• Figure 9: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
• Figure 10: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
• Figure 11: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
• Figure 12: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer

4.3 List of Tables

• Table 1: Top 10's Anti-angiogenic and Vascular Targeting Pipeline Drugs
• Table 2: Deals & Alliances in 2005
• Table 3: Deals & Alliances in 2004
• Table 4: Deals & Alliances in 2003
• Table 5: Companies with Cancer Anti-angiogenic Drugs on the Market
• Table 6: 2006 Q2 Sales Revlimid and Thalomid
• Table 7: 2006 Q2 Sales of Avastin
• Table 8: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
• Table 9: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
• Table 10: Drugs with Epidermal Growth Factor Receptor as a Target
• Table 11: Drugs with FMS-related Tyrosine Kinase 1 as a Target
• Table 12: Drugs with FMS-related Tyrosine Kinase 4 as a Target
• Table 13: Drugs with Kinase Insert Domain Receptor as a Target
• Table 14: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
• Table 15: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
• Table 16: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
• Table 17: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
• Table 18: Drugs with Protein Kinase C, beta 1 as a Target
• Table 19: Drugs with Ret Proto-Oncogene as a Target
• Table 20: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
• Table 21: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
• Table 22: Drugs with Vascular Endothelial Growth Factor as a Target
• Table 23: Breast Cancer Targets in Anti-Angiogenic Drug Development
• Table 24: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
• Table 25: Lung Cancer Targets in Anti-Angiogenic Drug Development
• Table 26: Prostate Cancer Targets in Anti-Angiogenic Drug Development
• Table 27: Renal Cancer Targets in Anti-Angiogenic Drug Development
• Table 28: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs
• Table 29: Recent Ceased or Discountinued Phase I to Phase III Anti-angiogenic and Vascular Targeting Drugs
• Table 30: Overview of Drugs in Phase III Clinical Development
• Table 31: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Breast Cancer
• Table 32: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Colorectal Cancer
• Table 33: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Lung Cancer
• Table 34: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Prostate Cancer
• Table 35: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Renal Cancer

相關商品

癌症相關市場調查報告書

乳癌、大腸癌、血管增生分析
Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌、淋巴癌、血管增生分析
Triple Analysis: Colorectal Cancer, Lymphoma and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌、黑色素細胞癌、血管增生分析
Triple Analysis: Colorectal Cancer, Melanoma and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

BioSeeker Group AB發行的製藥相關市場調查報告書

大腸癌、胰臟癌、血管增生分析

Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Angiogenesis

價格 : US $ 5175

出版日期 : 2012年01月

大腸癌、前立腺癌、血管增生分析

Triple Analysis: Colorectal Cancer, Prostate Cancer and Angiogenesis

價格 : US $ 5175

出版日期 : 2012年01月

大腸癌、細胞死亡、血管增生分析

Triple Analysis: Colorectal Cancer, Apoptosis and Angiogenesis

價格 : US $ 5175

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!